The Augmented Expression of the Cytidine Deaminase Gene by 5-Azacytidine Predicts Therapeutic Efficacy in Myelodysplastic Syndromes

Oncotarget - United States
doi 10.18632/oncotarget.26784
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Role of BCL2L10 Methylation and TET2 Mutations in Higher Risk Myelodysplastic Syndromes Treated With 5-Azacytidine

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Global Gene Expression Profile in Myelodysplastic Syndromes Using SAGE

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2008English

The Prognostic Significance of Chromosome 17 Abnormalities in Patients With Myelodysplastic Syndrome Treated With 5‐azacytidine: Results From the Hellenic 5‐azacytidine Registry

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

The Myelodysplastic Syndromes

Emerging Cancer Therapeutics
2011English

The Myelodysplastic Syndromes

Oncologist
Cancer ResearchMedicineOncology
1997English

528. Transgenic Expression of Cytidine Deaminase (CDD) for Myeloprotective Purposes

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2010English

Methylation and Expression of Mismatch Repair Gene Human mutS Homolog 2 in Myelodysplastic Syndromes

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Understanding the Myelodysplastic Syndromes

Oncologist
Cancer ResearchMedicineOncology
1997English

Myelodysplastic Syndromes

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy